A study published in the scientific journal Neurology in July 2020, showed that early deep brain stimulation (DBS) is safe and has benefit over standard medical therapy. Early DBS may reduce the risk of Parkinson disease progression.
The result of the newly published research study, in the scientific journal BMC Cancer, showed that patients diagnosed with high grade glioma who have the tumour marker (MGMT promoter methylation) lived longer than those who did not.
Our recently published study in the Journal of Neurology showed that medication dosage was reduced by an average of 32% within the first year after DBS, and remained stable at a reduced dose for 10 years. The types of medication taken could also be simplified.